

**SUPPLEMENTARY MATERIAL****SUPPLEMENTARY METHODS****ANTIBODIES AND REAGENTS**

The following antibodies and reagents were purchased: p16 (orb228122; Biorbyt, San Francisco, CA), phospho-ERK5 S496 (orb5183; Biorbyt, San Francisco, CA), NRF2 (GTX103322; Gentex, Irvine, CA), thioredoxin (TRX, 14999-1 AP20; Proteintech, Rosemont, IL), p90RSK (MAB 2056; R&D Systems, Minneapolis, MN),  $\alpha$ -tubulin (T5168; Sigma-Aldrich, St. Louis, MO); phospho-ERK5 TEY (3371; Cell Signaling Technology, Beverly, MA), ERK5 (3372; Cell Signaling Technology, Beverly, MA), phospho-p90RSK (9341; Cell Signaling Technology, Beverly, MA), p21 (2947; Cell Signaling Technology, Beverly, MA), p53 (9282; Cell Signaling Technology, Beverly, MA), heme oxygenase 1 (HO-1, ab13248; Abcam, Cambridge, MA), DNMT3A (NB12013888; Novus Biologicals, Centennial, CO), TNF $\alpha$  (NBP1-9532; Novus Biologicals, Centennial, CO), 53BP1 (NB100-304; Novus Biologicals, Centennial, CO), KLF2 (NBP2-61812; Novus Biologicals, Centennial, CO), GAS6 (BS-7549R; Bioss, Woburn, MA), Ki67 (ab92742; Abcam, Cambridge, MA), CD36 (100011, Cayman chemicals, Ann Arbor, MI), AHR (MA1-514; Invitrogen, Carlsbad, CA), PCNA (13-3900; Invitrogen, Carlsbad, CA), SUMO2/3 (M114-3, MBL Life Sciences, Woburn, MA), and Lamin B (LS-C82208; LSBio, Seattle, WA). CD11b (553310; BD Biosciences), and F4/80 (565410; BD Biosciences).

Protease inhibitor cocktail (p8340; Tocris (Minneapolis, MN), PMSF (36978; Tocris (Minneapolis, MN); NEM (E3876; Tocris (Minneapolis, MN); AX15836 (5843; Tocris, Minneapolis, MN); XMD 8-92 (S7525; Selleck chemicals, Houston, Tx); Lipofectamine 2000 transfection reagent (11668027; ThermoFisher Scientific, Waltham, MA); Mitosox Red (M36008; ThermoFisher Scientific, Waltham, MA); MitoNeoD (563761; MedKoo Biosciences, Inc, Morrisville, NC).

The ATP assay kit (ab83355; Abcam, Cambridge, MA), GM-CSF (415-ML-050/CF; R&D Systems, Minneapolis, MN); Seahorse XF Cell Mito Stress Test Kit (103015-100; Agilent Technology, Santa Clara, CA); Seahorse XF Glycolysis Stress Test (103020-100; Agilent Technology, Santa Clara, CA); Seahorse XF Base Medium (103334-100; Agilent Technology, Santa Clara, CA); Seahorse XF24 FluxPak mini (100867-100; Agilent Technology, Santa Clara, CA); ARE reporter kit (60514; BPS Biosciences, San Diego, CA); Chemiluminescence detection reagent kit (NEL105001EA; PerkinElmer, Waltham, MA); ApopTag peroxidase in situ apoptosis detection kit (S7100; Millipore, Burlington, MA); Efferocytosis kit (4649; Essen Biosciences, Ann Arbor, MI); NAD/NADH-Glo kit (G9071; Promega<sup>TM</sup> Corporation, Madison, MI).

AHR siRNA (SR427538; Origene Technologies, Rockville, MD).

The antibodies used in imaging mass cytometry (IMC) were described in Supplementary Table 1.

RRID number for each antibody, cells, software tools, mice, and plasmids were described in Supplementary Table 4.

**CONTACT FOR REAGENT AND RESOURCE SHARING**

45 Further information and requests for resources and reagents should be directed to and will be fulfilled  
46 by the Lead Contacts, Jun-ichi Abe ([jabe@mdanderson.org](mailto:jabe@mdanderson.org)) or Sivareddy Kotla  
47 ([skotla@mdanderson.org](mailto:skotla@mdanderson.org)).  
48

## 49 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

51 In this study, all animal procedures were performed in compliance with institutional guidelines and in  
52 accordance with research protocols approved by the Institutional Care and Use Committees of the  
53 Texas A&M Institute of Biosciences and Technology (2014-0231, 2017-0154) and The University of  
54 Texas MD Anderson Cancer Center (00001652, 00001109).  
55

### 56 **Generation of the ERK5 S496A KI mice:**

57 Mice containing ERK5 S496A point mutation (C57BL/6 background) were generated using the  
58 CRISPR/Cas technique. A detailed description of the method can be found in our two recent papers<sup>1,2</sup>.  
59 For confirmation of genotype, we performed PCR on genomic DNA from all pups, and the PCR  
60 products were sequenced to identify the correct point mutation and lack of any additional unwanted  
61 mutations surrounding the site of homology-directed mutagenesis. The primer pair used for PCR were  
62 5'-TCTAGCAGGCTTCGGTCATTGTC-3' (forward) and 5'-TGCACCTGACACCGTTGATC-3'  
63 (reverse). For Sanger sequencing of the PCR product, the primer 5'-  
64 AGGGTGCCATCTCCGACAATAC-3' was used.  
65

### 66 **Housing and Husbandry:**

67 Mice were housed in pathogen-free conditions at The University of Texas MD Anderson Cancer  
68 Center. The Program for Animal Resources is an AAALAC certified and defined pathogen-free facility  
69 for housing mice and rats<sup>3</sup>. A cage-level barrier system was used with an irradiated diet, ultra-filtered  
70 water, and heat-treated wood chip bedding. Enrichment material (nestlets) was provided. Cages and  
71 water were changed on a weekly basis. Animals were handled under a HEPA-filtered change station.  
72 Environmental parameters (ambient lighting, temperature, and humidity) were computer monitored as  
73 follows: 1) temperature: set point=22.2 °C (high limit=23.3 °C, low limit=21.1 °C), 2) humidity: set  
74 point=45% (high limit=55% and low limit=40%), 3) light-dark cycle: 12 hours of continuous light and  
75 12 hours of continuous darkness, and 4) air exchanges 10-15 times per hour. The vivarium was staffed  
76 7 days a week by animal caretakers, including weekends and holidays. Veterinary care and oversight  
77 were provided by a contract veterinarian who visited the facilities regularly and was available for  
78 consultation by phone or email.  
79

### 80 **Echocardiography:**

81 Cardiac function was assessed in *ERK5* S496A KI and wild type (WT) C57BL/6 control mice on a  
82 high-fat diet (HFD) for 16 weeks after each received a single injection of adeno-associated-virus-8  
83 overexpressing pro-protein convertase subtilisin/Kexin type 9 gain-of-function D377Y mutant (AAV8-  
84 PCSK9) at the age of 8-10 weeks as we previously described<sup>4</sup>. Echocardiograms of anesthetized mice  
85 were obtained using a Vevo2100 echocardiography machine equipped with an MS-550D 40-MHz  
86 frequency probe (VisualSonics). We performed anesthesia using 0.5-1 % isoflurane to maintain the  
87 heart rate at around 550 bpm for reducing suffering and distress. Left ventricular (LV) systolic and  
88 diastolic dimensions were measured in M-mode along the parasternal short axis of the LV. Fractional  
89 shortening was calculated using the following formula: %FS = 100% × (LV end-diastolic diameter –  
90 LV end-systolic diameter)/(LV end-diastolic diameter)<sup>5</sup>.

91  
92 **Tissue Preparation, Histologic Evaluation, and Quantification of Lesion Size in Conventional**  
93 **Model of Atherosclerosis in Mice Induced by AAV8-PCSK9 Transduction:**

94 In this model, we used only male mice for evaluating atherosclerotic lesions, because the size of  
95 atherosclerosis lesion was different between female and male. We randomly selected the mice from the  
96 pool of wild-type and ERK5 S496A KI male mice. We obtained rAAV plasmids encoding gain-of-  
97 function forms of murine *Pcsk9* (pAAV/D377Y-mPCSK9) from Addgene (plasmid #58376)<sup>6</sup>. PCSK9  
98 expression was driven by an efficient liver-specific promoter, HCEApoE/hAAT. Viral vectors in  
99 serotype 8 capsids rAAV8-D377Y-mPCSK9 were produced by the University of North Carolina  
100 Vector Core (Chapel Hill, NC). Viral vectors ( $1 \times 10^{11}$  titer/mouse) were delivered via a single tail vein  
101 injection into WT or ERK5 S496A mice at the age of 8-10 weeks; these animals had been fed an  
102 adjusted-calorie (high-fat) diet (HFD) consisting of 21% crude fat, 0.15% cholesterol, and 19.5%  
103 casein (TD.88137; Envigo, NJ)<sup>7</sup> for 16 weeks and then euthanized by CO<sub>2</sub> inhalation. In this AAV-  
104 PCSK9 injection model, according to the exclusion criteria established prior to the experiments, we  
105 excluded mice with LDL cholesterol level less than 300mg/dL after 16 weeks of HFD. The weight of  
106 each mouse was shown in Supplementary Fig. 1B.

107  
108 **Attrition:** We excluded total 4 mice with LDL cholesterol level less than 300mg/dL after 16 weeks of  
109 HFD.

110  
111 The arterial tree was perfused via the left ventricle with saline containing heparin (40 USPU/mL),  
112 followed by 10% neutral-buffered formalin in PBS for 10 minutes. The whole aortas and hearts of the  
113 mice were isolated. The full length of the aorta from the heart to the iliac bifurcation was dissected and  
114 opened along the ventral midline. *En face* preparations were washed in PBS, dipped in 60% isopropyl  
115 alcohol, and stained for 30 minutes with 0.3% Oil-Red-O that had been dissolved in 60% isopropyl  
116 alcohol. Stained images were captured with a digital camera mounted on a Nikon SMZ1000  
117 stereomicroscope and analyzed using ImageJ software.

118  
119 The aortic sinus area attached to the heart was dissected after fixation, and then embedded in paraffin.  
120 To examine the atherosclerotic lesions in the aortic valve area and necrotic core formation, serial  
121 sections (5  $\mu$ m) were taken throughout the entire aortic valve area and stained with hematoxylin and  
122 eosin (H&E) to assess the quantification of atherosclerotic plaque as we described previously<sup>7</sup>. We  
123 traced the internal elastic lamina and luminal boundary of the lesion manually and the lesion sizes of  
124 the aortic root were quantified by ImageJ software. To quantify necrotic core formation, we made serial  
125 sections through the entire aortic valve area and stained them with hematoxylin and eosin; the necrotic  
126 core area was quantified by the percentage of the non-cellular area and total lesion area using ImageJ  
127 software (<http://imagej.nih.gov/ij/>). The necrotic core area can be determined by examination of the  
128 acellular regions of these stained sections as previously reported<sup>8-10</sup>, and the necrotic core area was  
129 quantified as the percentage of the non-cellular area over the total lesion area. To prevent bias, the  
130 persons who evaluated the size of the plaque were blinded to the origin of the number of coded  
131 samples, not knowing the mouse genotypes and experimental conditions.

132  
133 **Hematoxylin and Eosin Staining:**

134 We fixed the slides in 10% buffered formalin for 15 min and washed them in double-distilled water  
135 (ddH<sub>2</sub>O). Next, we stained the slides with 0.1% hematoxylin for 3min followed by ddH<sub>2</sub>O washes, 95%  
136 ethyl alcohol, and ddH<sub>2</sub>O. Then we dipped the slides in 0.5% Eosin for 3 min, quickly rinsed with

137 ddH<sub>2</sub>O, dipped in 95% and 100% ethanol, incubated in 50:50 Xylenes:100% ethanol, and lastly  
138 incubated in 100% Xylenes. We mounted the slides using Permount with coverslips.

#### 140 **Immunofluorescence staining:**

141 The aortic valve area sections were incubated for 1 hour at 60 °C, deparaffinized in fresh xylene, and  
142 rehydrated through a graded alcohol series. After being washed with PBS, antigen retrieval was  
143 performed for 12 minutes at 95 °C in 10 mM sodium citrate buffer (pH 6.0) containing 0.05% Tween  
144 20. Slides were washed with PBS and treated with Dako Protein Block Serum-free (#S3020, Dako)  
145 containing 10% normal goat serum for 1 hour at ambient temperature to block non-specific antibody  
146 binding. The slides were incubated overnight at 4 °C with anti-MAC3 antibody (#550292, BD  
147 Biosciences; San Jose, CA) and anti-p53 antibody (#ab131442, abcam) or anti-TRX antibody (#14999-  
148 1-AP, Proteintech) or anti-DNMT3a antibody (#NB120-13888, Novus). After being washed with PBS-  
149 T (PBS containing 0.2% Tween 20) and PBS, the slides were incubated with Alexa488 anti-Rabbit  
150 secondary antibody (1:2000, #A11055, Invitrogen) or Alexa488 anti-Mouse secondary antibody  
151 (1:2000, #A11029, Invitrogen), Alexa546 anti-Rat secondary antibody (1:2000, #A11081, Invitrogen),  
152 and DAPI (2.5 ug/mL, #D1306, Invitrogen) for 1 hour at ambient temperature. After being washed  
153 with PBS-T (PBS containing 0.2% Tween 20) and PBS, the cover slips were mounted.  
154 Immunofluorescence images of heart sections were captured by Olympus FX1200 MPE confocal laser  
155 scanning microscope.

#### 157 **Representative Image selection:**

158 Representative images were selected based on the most accurate representation of similarity with the  
159 mean value of each experimental group from all experiments performed for each experiment and  
160 group, which were evaluated in a blinded manner.

#### 162 **Mouse Monocyte and Macrophage Culture:**

163 Bone marrow cells were isolated by flushing the femurs and tibias of C57BL/6 WT mice (000664;  
164 Jackson Laboratory) or ERK5 S496A KI mice on the C57BL/6 background under a normal chow diet or  
165 after 4 months of an HFD and AAV-PCSK9 injection as described previously<sup>2</sup> and in each figure legend,  
166 and differentiated into macrophages by culturing at a density of 1x10<sup>6</sup> cells/mL in Iscove's Modified  
167 Dulbecco's Medium (IMDM) (#13390, Sigma-Aldrich, St. Louis, MO) containing 10% fetal bovine  
168 serum (FBS), 10% (v/v) spent medium of L929 cell (NCTC clone 929 CCL-1<sup>TM</sup>; ATCC, Manassas, VA)  
169 cultures as the source of macrophage colony-stimulating factor <sup>11</sup>, 1% HEPES, and 1% penicillin-  
170 streptomycin for 5-8 days at 37 °C and 5% CO<sub>2</sub> in air.

#### 172 **Cell Line Authentication:**

173 BMDMs were validated by flow cytometry and were typically >90% CD11b<sup>+</sup> and F4/80.

### 175 **METHOD DETAILS**

#### 177 **Transfection:**

178 Cells were transfected with the appropriate plasmid DNAs using Lipofectamine 2000 transfection  
179 reagent according to the manufacturer's instructions. After transfection, cells were allowed to recover  
180 in the complete medium for 24 hours.

#### 182 **Western Blot Analysis:**

183 Cells were washed twice with cold PBS, and whole-cell lysates were prepared in RIPA buffer (50 mM  
184 Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P40, 0.1% SDS, 1 mM dithiothreitol,  
185 1:200-diluted protease inhibitor cocktail [P8340, Sigma-Aldrich], and 1 mM PMSF), western blot  
186 analysis was performed as we described previously<sup>2</sup>. Tubulin was used as the loading control and was  
187 always probed together with the specific protein of interest. In most cases, tubulin immunoblots were  
188 not shown to save space. To obtain a fold-increase value, the intensity of each band was measured by  
189 Image J, and the mean intensity (integrated optical density) at the baseline (control) for each  
190 experiment was calculated from more than or equal to 5 replicates, then normalized to tubulin  
191 expression and designated as 1. We calculated a fold increase from this mean intensity at the control  
192 with every band's intensity performed in each experiment.

193

#### 194 **Immunoprecipitation (SUMO assay):**

195 Cells were collected in PBS containing 10 mM N-ethylmaleimide (NEM), and cell extracts were  
196 prepared in SUMOylation buffer (50mM Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EDTA; 1 mM  
197 EGTA; 1% Nonidet P-40; 0.1% sodium dodecyl sulfate (SDS); 0.25% Sodium Deoxycholate; 1 mM  
198 Na<sub>3</sub>VO<sub>4</sub>; 1:200-diluted protease inhibitor cocktail (Sigma, St.Louis, MO); 1 mM PMSF; and 10 mM  
199 NEM). SUMOylation was detected by immunoprecipitation analysis as previously described<sup>12</sup>. Briefly,  
200 Cell lysates were centrifuged at 12,000 g for 30 min at 4 °C. Protein concentrations were determined by  
201 a BCA protein quantification assay kit (Pierce). 0.5 mg lysates were immunoprecipitated with a  
202 polyclonal rabbit anti-NRF2 (GTX103322; Gentex, Irvine, CA) or anti-rabbit IgG (ab37415; abcam)  
203 and incubated overnight at 4 °C. After that, 40 ul of the Protein A/G Dyna beads were added to the  
204 antibody-protein mixture and incubated for 4 hrs at 4<sup>o</sup>C. Immunocomplexes were separated by a  
205 magnet stand followed by five washes with SUMOylation lysis buffer and subjected to Western  
206 blotting with mouse anti-SUMO2/3.

207

#### 208 **Real-time PCR (qRT-PCR):**

209 At the end of experiments, cells were washed 3 times with PBS and total RNA was isolated with  
210 TRIzol reagent (Invitrogen, #15596026). qTR-PCR was performed as we previously described<sup>2</sup>. Each  
211 reaction mixture (10µl) contained cDNA synthesized from 20 ng of total RNA, 5 µl of iQ SYBR Green  
212 Supermix (1708882; Bio-Rad, Hercules, CA 94547), and 0.5 µmol/l each of forward and reverse  
213 primer (IDT) with qSTAR quantitative PCR primers shown in Supplemental Table. Reactions were  
214 performed in triplicate. qRT-PCR data acquisition was carried out using the CFX96 TouchTm Real  
215 Time detection System (Bio-Rad) and SYBR Green (Bio-Rad) at thermal activation for 10 minutes at  
216 95°C and 40 cycles of PCR (melting for 15 seconds at 95°C, followed by annealing/extension for 1  
217 minute at 60°C). The comparative C<sub>t</sub> (<sup>2</sup>-<sup>ΔΔC<sub>t</sub></sup>) method was used to relatively quantified changes in  
218 mRNA expression of samples, in which cycle threshold (Ct) values of target genes were normalized to  
219 that of the reference genes<sup>13</sup>. All qRT-PCR primers were obtained from Sigma-Aldrich. The sequences  
220 of qRT-PCR primers were listed in the Supplementary Table 1.

221

#### 222 **Efferocytosis Assay:**

223 BMDMs were cultured in IMDM containing 10% (v/v) FBS (Hyclone), 1% HEPES, and 1% penicillin-  
224 streptomycin, efferocytosis assay was performed as we described previously.<sup>2</sup> We measured  
225 efferocytotic activity using IncuCyte ZOOM live cell imaging (ESSEN Bioscience, Ann Arbor, MI).  
226 Engulfment of pHrodo-labeled cells induces pHrodo fluorescence by the phagosome's acidic  
227 environment, and the fluorescence intensity of the image was determined using IncuCyte ZOOM, as we  
228 previously reported<sup>14</sup>.

229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273

**ATP Assay:**

Intracellular ATP concentrations were measured using the ATP Assay Kit Colorimetric/Fluorometric (Abcam ab83355) per the manufacturer's protocol.

**Metabolic Extracellular Flux Analysis (Seahorse):**

25,000 BMDMs/well were seeded into Seahorse XF24 cell culture microplates 16 hours before the assay and cultured with XF medium. Then, cells were cultured in Seahorse XF Base Medium supplemented with 1 mM pyruvate, 2 mM glutamine, and 10 mM D-glucose for the Seahorse XF cell mito stress test and with 1 mM glutamine for the Seahorse XF glycolysis stress test. The cell culture microplate was placed in a 37 °C non-CO<sub>2</sub> incubator for 1 hour and then loaded onto Seahorse XF24 to measure OCR and ECAR using a Seahorse XF24 Extracellular Flux Analyzer (Agilent, Santa Clara, CA) as we described previously<sup>2</sup>.

**ERK5 Transcriptional Activity:**

We detected ERK5 transcriptional activity as we described previously<sup>2, 14</sup>.

**NRF2-ARE Transcriptional Activity:**

We detected NRF2-ARE transcriptional activity as we described previously<sup>14</sup>. Transfections were performed in triplicate, and each experiment was repeated at least 5 times.

**NF-κB Activity:**

NF-κB activity was measured as we previously described<sup>2</sup>. BMDMs were transfected with a mixture of the NF-κB-Luc and pRL-TK vectors (encoding Renilla luciferase) using Lipofectamine 2000 in Opti-MEM according to the manufacturer's instructions. The cells were harvested and assayed for firefly and Renilla luciferase activity using the Promega Dual-Luciferase Reporter Assay System.

**Mitochondria-Specific ROS Measurements (MitoNeoD and MitoSOX Red):**

We measured mitochondria-specific ROS as we described previously<sup>2, 14</sup>. In brief, cells were incubated with MitoSOX Red (5 μM) (#M36008, Invitrogen, Eugene, OR), and fluorescence intensity was measured with excitation at 510 nm and emission at 580 nm using a plate reader (FLUOstar Omega, BMG LABTECH, Cary, NC). We set the mean level at control = 1, and calculate the "fold increase" for each measurement.

Since the non-specific detection of MitoSOX Red has been suggested, we also performed MitoNeoD methods to detect mitochondrial ROS<sup>15</sup>. MitoNeoD contains an O<sub>2</sub><sup>•-</sup>-sensitive reduced phenanthridinium moiety modified to prevent DNA intercalation. A carbon-deuterium bond enhances MitoNeoD's selectivity for O<sub>2</sub><sup>•-</sup> over non-specific oxidation. Lastly, a triphenylphosphonium lipophilic cation moiety of MitoNeoD induces rapid accumulation within mitochondria. Cells were seeded into 96 -well black, clear-bottom tissue culture plates at 10,000 cells per well and were treated as indicated in each figure. After indicated time points, cells were washed with HBSS buffer, and incubated with 5 μM MitoNeoD for 20 min at 37°C. After washing three times with HBSS buffer, fluorescence intensities were measured using a plate reader (FLUOstar Omega-BMG LABTECH) with excitation, and emission wavelengths were 544 and 605 nm, respectively (MitoNeoD). The fluorescence intensity values of each unstained sample were subtracted from the fluorescence intensity values of the stained sample (either treated with

274 oxLDL or vehicle) to remove the background fluorescence and to obtain the net fluorescence intensity  
275 values. We set the stained sample's mean fluorescence intensity at control = 1, and calculate the “fold  
276 increase” for each measurement.

277

### 278 **Migration assay in Boyden chambers:**

279 Transwell assay was performed via Boyden chamber with 8.0µm pore size (Corning, CLS3422) as  
280 described previously<sup>16</sup>. The bottom chamber surface of the membrane was coated with 0.1% matrigel  
281 (356234; BD Biosciences) for 30 min. BMDMs were incubated in serum-free IMDM medium at 37°C  
282 and 5% CO<sub>2</sub> for 2 hours before the assay. Added 500 µl serum-free IMDM medium with oxLDL (10  
283 µg/ml) or vehicle control to the lower chamber. BMDM (1.5 × 10<sup>5</sup> cells/mL) was added to the upper  
284 chamber and incubated at 37°C and 5% CO<sub>2</sub> incubator for 20 h. After incubating at 37°C in 5%  
285 CO<sub>2</sub> for 20 hours, non-migrated cells were scraped from the upper surface of the filter. BMDMs on the  
286 lower surface were fixed with 4% paraformaldehyde for 20 minutes at room temperature, washed three  
287 times with PBS, and stained with crystal violet (0.1%; Sigma (Cat# V5265) for 20 min at room  
288 temperature. We determined the number of BMDMs on the lower surface of the filter by counting five  
289 random high-power (200×) fields of constant area per well by inverted microscope (BZ-X810;  
290 Keyence). Experiments were performed in triplicates, from five independent experiments.

291

### 292 **In Situ TUNEL Assay:**

293 TUNEL staining was performed using the ApoTag peroxidase *in situ* apoptosis detection kit (#S7100,  
294 Millipore) as we described previously<sup>17</sup>.

295

### 296 **Annexin V Apoptosis Assay:**

297 Annexin V apoptosis assay was performed using annexin V-fluorescein isothiocyanate (annexin V-  
298 FITC apoptosis detection kit (ab14085, Abcam, Cambridge, MA) as we described previously<sup>14</sup>.

299

### 300 **Serum Lipid Profile Analysis:**

301 The levels of cholesterol (HDL, LDL) were determined using a cholesterol assay kit for mice (EHDL-  
302 100, Bioassay System, Hayward, CA) as we described previously<sup>14</sup>.

303

### 304 **RNA-seq data analysis:**

305 We used Top Hat program (v2.0.12) with default parameters to map all paired-end RNA-seq reads to  
306 the mouse genome (Mus musculus GRCm38). Gene expression and significance of DEGs were  
307 calculated by Cuffdiff (v2.0.12). DEGs were defined by Cuffdiff according to *Q* value ≤0.05 as a  
308 threshold. We calculated *p* value for each GO term with a modified Fisher's exact test on DAVID  
309 website (<https://david-d.ncifcrf.gov>). Hallmark analysis was performed by Gene Set Enrichment  
310 Analysis (GSEA v4.2.1). We used the R package “GOplot” to perform GO bubble plot, GO circle plot,  
311 and GO chord plot.

312

### 313 **NAD<sup>+</sup> Measurement levels:**

314 Total intracellular NAD<sup>+</sup> was measured using the NAD/NADH-Glo Bioluminescent Assay Kit  
315 (G9072; Promega Corporation, United States), according to the manufacturer's instructions. BMDMs  
316 were lysed with dodecyl trimethyl ammonium bromide and treated to neutralize their counterparts. To  
317 measure NAD<sup>+</sup>, the extract was treated with 25 µL of 0.4 N HCl and heated at 60°C for 15 min,  
318 incubated at RT for 10 min, following the addition of 25 µL Trizma base. Next, the equal volume of  
319 NAD/NADH-Glo TM detection reagent was added to each well and incubated for 30 minutes at room

320 temperature. The intensity of light (proportional to the amount of NAD<sup>+</sup>) was detected by a  
321 luminometer (BGS Microplate Reader; BGS).

### 323 **Cytokine Profile in Mouse serum:**

324 Mouse Inflammatory Array (AAM-INF-1-4, Ray Biotech, Inc) were used according to the  
325 manufacturer's instructions. Cytokine array membranes were incubated in equal quantities of serum  
326 either from WT-HFD or ERK5S496A-HFD at 4<sup>0</sup>C for overnight. After washing with wash buffer,  
327 membranes were incubated in biotin-labeled primary antibodies, followed by 1,000-fold diluted HRP-  
328 conjugated streptavidin added and developed. After development, films were scanned, and the images  
329 were processed and quantified using ImageJ software (National Institutes of Health). The relative  
330 intensity was quantified using densitometry with ImageJ software with reference to the positive  
331 controls on the membrane.

### 333 **Senescence associated (SA) β-Galactosidase Activity in cell cultures:**

334 β-galactosidase activity was detected in cells using by GlycoYELLOW<sup>TM</sup> - βGal Kit (SCTO24) from  
335 Millipore Sigma. β-galactosidase detection was carried out according to the manufacturer's  
336 instructions. The images were taken using Incucyte. SA-β-gal staining positive cells were quantified  
337 based on three independent images from different regions of the staining.

### 339 **Flowcytometry of senescence associated cell stemness analysis:**

340 BMDMs were treated with Bafilomycin A1, followed by incubation with C12FDG (Molecular Probes/  
341 Life technologies), which is a fluorogenic substrate for β-gal activity, for 2 h at 37°C with 5% CO<sub>2</sub> as  
342 described previously<sup>18</sup>. After that, cells were washed with PBS, harvested by scraping, centrifuged, and  
343 fixed with fixation buffer for 30 min at 4°C. Cells were washed once with FACS staining buffer,  
344 centrifuged, and after discarding the supernatant, the pellet was suspended in permeabilization buffer  
345 and incubated for 5 min at 4°C. After centrifugation, the pellet was resuspended in FACS staining  
346 buffer and incubated with anti-Ki67 primary antibody at 4<sup>0</sup>C for 1 hr. Cells were washed three times  
347 and then incubated with a secondary antibody for 1 hr at room temperature, followed by three times  
348 washing and analyzed by flow cytometry. Data were analyzed using Flowjo software. Live cells were  
349 selected based on the side and forward scattered. Fluorescence-stained gates were set up based on the  
350 unstained samples, and compensation was set up based on single-stained controls. We also performed  
351 the p53BP1 and Ki67 double staining for detecting double positive cells with anti-p53BP1 (NB100-304;  
352 Novus Biologicals, Centennial, CO) as described above.

### 354 **Imaging Mass Cytometry (IMC)**

356 The antibodies are conjugated with rare-earth-metal isotopes of defined atomic masses, which allows  
357 the antibody bound proteins to be separated by a mass cytometer. The tissue was laser-ablated spot by  
358 spot and line by line, and the ablated materials were transported to the CyTOF mass cytometer by a  
359 mixed argon and helium stream. The 23 transient and single isotope signals were plotted using the  
360 coordinates of each single laser shot; by overlaying all analyzed measurement channels as described  
361 previously<sup>19</sup>. The Fluidigm Hyperion Imaging system allows the simultaneous detection of >20  
362 parameters in a single tissue sample while eliminating the common challenges of conventional  
363 immune-histochemical analysis, such as signal fading, auto-fluorescence, signal linearity, and spectral  
364 overlap.



366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410

### ***Antibody panel for IMC and antibody conjugation***

We used 26 antibodies and Ir DNA-Intercalator (Cell-ID Intercalator-Ir; Fluidigm #201192A) for IMC, as listed in Supplemental Table 1. The markers (Na/K ATPase, alpha smooth muscle actin and TCR $\beta$ , which are not included in Supplemental Table 1) showed no signal or non-specific staining and served as negative controls. The antibodies listed in Supplemental Table 1, except for the metal-conjugated antibodies that were purchased from Fluidigm, were conjugated to metals using the Maxpar X8 Multimetal Labeling Kit (Fluidigm) according to the manufacturer's protocol. To determine optimal antibody concentrations, 3 different concentrations of each metal-labeled antibody were tested by IMC prior to being used in antigen expression analyses (see below).

### ***Tissue staining with metal-conjugated antibodies for IMC***

Hearts were harvested and fixed for 24 hours in 10% formalin and embedded in paraffin after the dehydration procedure by an automated tissue processor (LEICA, TP1020). A paraffin tissue section microarray (TMA) was built using 7 independent WT samples and 6 independent ERK5 S496A KI samples from 3-mm 13 tissue block cores. The cores were embedded in a large paraffin block, which was then sectioned and mounted onto a TMA slide. The TMA slides consisted of tissues containing the aortic valve area, and the section thickness was 5  $\mu$ m. H&E staining was performed to confirm that all cores have atherosclerotic plaques in the aortic valve area and to determine the position and size of atherosclerotic plaques.

TMA slides were incubated for 16 hours at 60 °C, deparaffinized in fresh xylene, and rehydrated through a graded alcohol series. After the slides were washed with TBS-T (TBS containing 0.1% Tween 20, pH 7.6) and TBS, antigen retrieval was performed for 15 minutes at 95 °C in 10 mM sodium citrate buffer (pH 6.0) containing 0.05% Tween 20. Slides were washed with TBS-T and TBS and treated with TBS containing 1% normal donkey serum and 3% BSA for 2 hours at ambient temperature to block non-specific antibody binding. The slides were incubated overnight at 4 °C with 26 metal-conjugated antibodies, as described in Supplemental Table 1. After being washed with TBS-T and TBS, the slides were incubated with 5 nM Ir DNA-Intercalator (Fluidigm) that had been diluted in TBS for 5 minutes at ambient temperature. After being washed with TBS and doubly distilled H<sub>2</sub>O, the slides were immediately dried with pressurized air. After 1 or 2 days, the slides were scanned by the Hyperion Imaging System (Fluidigm), as described below.

### ***IMC image acquisition***

Regions of interest (ROIs) were chosen manually based on the plaque position and shape, which was identified by earlier H&E staining. Of note, between the WT cores and the ERK5 S496A KI cores, we intentionally selected similar plaque sizes for ROI because we intended to characterize the plaque composition of a similar plaque developmental stage.

Data acquisition was performed on a Helios time-of-flight mass cytometer coupled to a Hyperion Imaging System (Fluidigm). Prior to laser ablation, optical images of slides were acquired using Hyperion software, and the ROI to ablate was selected as described above. Laser ablation was performed at a resolution of approximately 1  $\mu$ m and a frequency of 200 Hz. In total, 18 image stacks from 7 WT samples and 18 image stacks from 6 ERK5 S496A KI samples were acquired.

### ***IMC data analysis***

411 MCD format (.mcd) files that were generated after data acquisition were converted to multi-TIFF  
412 images using the MCD viewer (Fluidigm). The TIFF images were loaded using VIS software  
413 (Visiopharm; Hoersholm, Denmark) to generate the database. First, we created an analysis protocol  
414 package for cell segmentation, trained by the nuclear staining by Ir DNA-Intercalator, to define cell  
415 borders in the VIS software. After cell segmentation, we defined another analysis protocol package for  
416 phenotyping that was trained by the expression level information of functional markers and cell-type  
417 markers across all images. For some markers in the analysis protocol package, the threshold was  
418 applied to separate EC-like clusters and MC-like clusters. We analyzed 19,476 cells in WT ROIs and  
419 14,680 cells in ERK5 S496A KI ROIs; 9 phenotypic clusters were identified in both WT and ERK5  
420 S496A KI ROIs. To measure the expression level of each marker per cell and the distance among cells,  
421 we added the calculation of mean intensity of each marker in each cluster per cell and the calculation of  
422 object distance between 2 different clusters per cell into the output variable part of the analysis protocol  
423 package. After running the batch process containing all analysis protocol packages, we obtained the  
424 phenotype matrixes, the t-SNE plots, the intensity of each marker per cell, and the cell-cell distance  
425 information. We used GraphPad Prism 8 (GraphPad; San Diego, CA, USA) to create graphs and violin  
426 plots.

427

428 The intensity was determined using mass cytometer counts, which were scaled to 16-bit pixel values  
429 when the images were exported. These exports created the base intensity measurements for each pixel;  
430 the mean intensity in the cellular segmentation was calculated by accumulating pixels. We selected the  
431 molecules, which showed a median expression level  $>0.25$  (intensity) in MCs and  $0.19$  (intensity) in  
432 ECs; the up-regulation and down-regulation of intensity between WT and ERK5 S496A KI mice were  
433 consistent among all the MC-like clusters. On the basis of the large IMC data set ( $n>500$ ), the value  
434 that met both unpaired t test with Welch's correction  $P<0.01$  and Mann Whitney test  $P<0.01$  was  
435 considered statistically significant based on the previous recommendations<sup>20, 21</sup>.

436

437 We analyzed key molecules that differentiate between the phenotype and functional status of  
438 endothelial cells and macrophages in relation to the atherosclerotic plaque. To determine the role of  
439 ERK5 S496 phosphorylation in regulating SASP and DDR events, we selected antibodies against the  
440 molecules associated with 1) senescence, 2) inflammation, 3) efferocytosis, 4) antioxidant, and 5) DDR  
441 that had demonstrated the normal distribution of their expression signals. The 26 transient and single  
442 isotope signals were plotted using the coordinates of each laser shot; by overlaying all analyzed  
443 measurement channels, we generated a high-dimensional image of the atherosclerotic plaques obtained  
444 from WT and ERK5 S496A KI mice. Using the VISIOPHARM program (Hoersholm, Denmark), we  
445 found that single-cell features were computationally segmented with a watershed algorithm (Fig. 2B).

446

447 Single cell marker or molecule expression data were extracted. These single-cell data were analyzed  
448 using the Phenomap module, which adds functionality for automatically clustering high-parameter  
449 datasets, generating t-SNE plots (Fig. 2D) and the phenotype or cluster matrix (Fig. 2E) using a  
450 clustering algorithm (each cluster's elements are shown in Figure 2E). Using the trained analysis  
451 protocol package, the unsupervised clustering algorithm across all images was used to divide identified  
452 cells into the identified clusters and further visualize them on a phenotypic matrix and tSNE plots. Of  
453 note, since we characterized cell composition and molecule expression in each plaque, we intentionally  
454 selected similar sized plaques from ERK5 S496A KI and WT mice for IMC analysis.

455

456 **Power calculation:**

457

458 Our preliminary studies showed the coefficient of covariation was about 30%. A sample size of 15 mice  
459 in each group was expected to have 90% power to detect an effect size of 1.226-SD at a two-sided  
460 significance level of 0.05 using two-sample t-test. The effect size of 1.226 corresponds to about 36%  
461 mean change between the two groups, for example, atherosclerosis lesion size between wild-type and  
462 ERK5 S496A KI groups.

463

#### 464 **Statistical Analysis:**

465

466 Statistical analysis was performed using GraphPad Prism software ver. 9.0.0 (San Diego, CA, USA).  
467 First, we performed the Shapiro-Wilk test to check the normality of each group. Since the number was  
468 too large, we performed D'Agostino & Pearson test to check the normality of each group described in  
469 Fig. S2G. Comparisons among more than two groups were performed using ordinary one-way or two-  
470 way analysis of variance (ANOVA) followed by Tukey post hoc multiple comparisons test after the  
471 data passed the Shapiro-Wilk normality test. An unpaired Student's t-test (two-tailed) was applied for  
472 comparing the two groups also after the data passed the Shapiro-Wilk normality test. Data that failed  
473 the normality test, the Mann-Whitney U test was used to analyze two-group comparisons, and Kruskal-  
474 Wallis followed by Dunn post hoc multiple comparisons test for multi-group comparisons. *P* values  
475 <0.05 were considered statistically significant, except IMC data analysis, and are indicated by 1  
476 asterisk in the figures. *P* values <0.01 are indicated by 2 asterisks. We performed all experiments  
477 independently unless specifically stated.

478

479 For analyzing Western blot analysis, we used ECL detected by CCD imager, and quantified Western  
480 blot based on the guideline described by Degasperi et al.<sup>22</sup> We divided all data points from a replicate  
481 by a normalization point in that replicate. The normalization point, which was the most reproducible  
482 condition, was selected. We selected medium-intensity points to avoid the lowest and highest-intensity  
483 data points based on the guideline described in Degasperi et al.<sup>22</sup> The normality assumption cannot be  
484 verified based on the data acquired in the study. However, we followed the guideline described by  
485 Degasperi et al.,<sup>22</sup> who reported that by following their guideline, we could obtain the data within a  
486 linear dynamic range, minimize the coefficient of variation of the normalized data, and assume the  
487 normality. We also published multiple papers and detected the expression of the same molecules in the  
488 same cells (bone marrow-derived macrophage) derived from ERK5 S496A KI and wild-type cells  
489 using the same Western blotting techniques and antibodies.<sup>2, 14</sup> Combining these data from our lab also  
490 supports the normality assumption of our Western blot data. Moreover, for Western blot experiments,  
491 since we obtained each experimental data set as an average of a large number of cultured cells, we  
492 assumed the data was normally distributed based on the central limit theorem.

493

494 For analyzing IMC data with the SAS group (Fig.3A-E), first, to exclude the non-senescent and  
495 proliferative cells (low p53 and low Ki67 MCs), we calculated the two-dimensional density of  
496 expression of Ki67 and p53 by "kde2d" function of R and selected cells to involve in the further  
497 analysis according to density<0.1 by using spatialEco R package<sup>23</sup> as shown in Fig.3A. In Figure 3A,  
498 585 cells were grouped using the threshold of 0.1. To have a fair comparison, we set the number of  
499 cells to be grouped to 585 in Fig. S2H, I, and J, which has the same grouped cells number (585 cells) as  
500 shown in Fig. 3A. We ranked the density of each cell, and then obtained cells with the lowest 585  
501 densities to be grouped. Next, to determine the different distribution pattern groups of the cells, we  
502 calculated log scaled ratio of Ki67 and p53 of selected cells by  $\log_{10}(\text{expression of Ki67}/\text{expression of$

503 p53), and we further calculated the one-dimensional density of this log-transformed ratio. Because the  
504 one-dimensional density distribution of this parameter was trimodal, MCs can be divided into three  
505 groups based on different patterns of p53:Ki67 expression (Fig. 3A) and two groups (Fig.S2H and S2J)  
506 with the cutoff values -1.01 and -0.024 (Fig. 3B), -0.072 (Fig.S2H), and -0.633 (Fig.S2I), respectively.  
507 To calculate the significance of the proportion between WT and ERK5S496A in each group, we used  
508 the boosting algorithm. We sampled 500 cells from all cells to calculate the proportion of group 1, 2,  
509 and 3 by using base R package with the sample function. We repeated the sampling 1,000 times.  
510 Wilcoxon test was performed to estimate  $p$  values between wild type and knocked-in cells in three  
511 groups (Fig.3C-E).

512  
513 Random effects modeling can be useful in the presence of hierarchical observations. As noted by  
514 Krzywinski, Altman, and Blainey<sup>24</sup>, this modeling approach is useful for understanding sources of  
515 variability in the hierarchy of the subsamples and can reduce the cost of the experiment. Reductions in  
516 cost may occur if intra-class correlations are large. While partitioning sources of variability may be  
517 interesting when one cares about inferences at multiple levels of the hierarchy, choosing fixed effects  
518 ANOVA in our setting as an alternative should not be considered an invalid approach to analysis. Our  
519 inference is focused on the mean-shifts in distribution. As Krzywinski et al. noted<sup>24</sup>, the random effects  
520 approach may provide more power (less false negatives for the same false positive rate). While we  
521 have conducted statistical analysis without partitioning the variance into hierarchical components  
522 (which is less powerful), we have numerous significant statistical findings, despite the reduction in  
523 power.

524  
525 Please check the IMC method section for the statistical analysis with the IMC data set.

526  
527 Statistical information, including the  $n$  of each group, the normality test results, the applied statistical  
528 methods, and  $P$  values for each figure, are summarized in Table S3.

529  
530 **Controls for each relative value:**

531 Controls for each relative value were described in Supplementary Figure 4.

532  
533 **Data availability:**

534 The RNA-seq data was deposited in the NCBI's Gene Expression Omnibus database (accession  
535 GSE210949). All other data supporting the findings of this study are available within the article or its  
536 supplemental materials.

537  
538 Please see the Major Resources Table in the Supplemental Materials.

539

540 **SUPPLEMENTARY DISCUSSION**

541

542 One of the defining characteristics of senescent cells is their cell cycle arrest<sup>25, 26</sup>. The activation of two  
543 pathways of (p53/p21 and p16/Rb) plays a crucial role to control senescence-induced cell cycle arrest<sup>25</sup>.  
544 When we co-plotted p53 and Ki67, which is used as a proliferation marker in the atherosclerosis  
545 lesions<sup>27</sup>, we found a clear relationship between p53 and Ki67 showing that p53 played a role in  
546 inducing cell cycle arrest in Groups 1 and 3 in myeloid cells (Fig. 3A), and also in vascular smooth  
547 muscle cells (VSMCs) (Fig. S2J). Milanovic et al. have defined SAS as “an unexpected, cell-  
548 autonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from the  
549 cell-cycle blockade”<sup>28</sup>. Since p53 is a major cell-cycle blockade mechanism in macrophages during  
550 atherosclerosis formation<sup>29</sup>, we investigated the relationship between p53 and Ki67 in the plaque. We  
551 found that some of the myeloid cells escape from the p53-mediated cell-cycle blockade, which was  
552 defined as Group 2 in Fig. 3A. One of the important characteristics of SAS is “escaping from cell-cycle  
553 arrest”, and we found that in Group 2 MCs, p53 and Ki67 were linearly co-expressed ( $y = 0.92x +$   
554  $0.81$ ; F test  $p$  – value  $< 0.001$ ). If p53 maintains its function as a cell-cycle blocker, the expression  
555 of p53 and Ki67 should not be linear as shown in Group 1 and 3 in both MCs and VSMCs. Group 1  
556 had a high p53 expression-mediated anti-proliferation (low Ki67 level) whereas Group 3 had a low p53  
557 expression-mediated high proliferative capacity (high Ki67 level) (Fig.3A). Of note, we did not observe  
558 the features of Group 2 in ECs (Fig. S2I) and VSMCs (Fig.S2J), indicating that SAS uniquely occurred  
559 in MCs.

560

561 In order to evaluate the induction of senescence in the plaque, we initially proposed to compare the  
562 vessels from the atherosclerotic and non-atherosclerotic mice. However, we realized that this is  
563 difficult because the cell composition differs between plaque and non-plaque intima. For instance, there  
564 are very few myeloid cells in the non-plaque intima<sup>30, 31</sup>, and it is not practical to compare the MCs in  
565 the condition with such differences in cell numbers. It has been reported that circulating monocytes  
566 derived from bone marrow accumulate continuously during atherosclerosis formation, which strongly  
567 links to lesion size and hypercholesterolemia (HC)<sup>30, 32</sup>. Therefore, we compared the phenotypes of  
568 BMDMs from HC and non-HC mice, which reflects the phenotypes of the myeloid cells accumulated  
569 in the plaque. We found evidence for SASP induction in BMDMs isolated from HC mice. By using  
570 these BMDMs, we also evaluated two senescence markers (p53-binding protein 1 (53BP1) and LAMIN  
571 B1) and a cell growth marker (proliferating cell nuclear antigen (PCNA)) as evidence for SAS in HC-  
572 mediated reprogrammed BMDMs. We observed an increase of 53BP1 and PCNA, and a decrease of  
573 LAMIN B1 expression in HC WT-HFD mice (HFD BMDMs) compared to NC WT-NCD mice (NCD  
574 BMDMs) (Fig. 3F and Fig. S3). Furthermore, we also found double SA $\beta$ -gal and Ki67 positive (SA  $\beta$ -  
575 gal<sup>+</sup>Ki67<sup>+</sup>) (Fig. 3L, M), and double 53BP1 and Ki67 positive (53BP1<sup>+</sup>Ki67<sup>+</sup>) macrophages (Fig. 3N,  
576 O) from the HC WT-HFD mice (Fig. 3L-O). All these findings are suggestive of an induction of SAS  
577 by HC in myeloid cells.

578

579 Therefore, we have three lines of evidence supporting our hypothesis of induction of SAS by HC in  
580 myeloid cells: (1) the escape from the cell-cycle arrest as shown by linear co-expression of p53 and  
581 Ki67 in the plaque; (2) the induction of both SASP and proliferation markers in BMDMs from HFD  
582 BMDMs compared to those from NCD BMDMs; and (3) the existence of double positive macrophages  
583 of SA  $\beta$ -gal<sup>+</sup>Ki67<sup>+</sup> 53BP1<sup>+</sup>Ki67<sup>+</sup> from HFD BMDMs. We also plotted p16 and Ki67 in MCs *in vivo*.  
584 Although we did see some tendency for the existence of Groups 2 and 3, there was no evidence for a

585 Group 1. (Fig.S2H). Cudejko et al. have reported that p16 deficiency does not module macrophage  
586 cell-cycle progression<sup>33</sup>. Therefore, p16 is unlikely to play a key role in the regulation of macrophage  
587 proliferation. Also, p16 expression intensity was relatively lower than p53 expression (Fig.S2G),  
588 blurring the picture for Group 1.

589

590 We found the upregulation of p16 (#7 and #9) and p-PKC $\zeta$  (#1, #7, and #9) expression in the ERK5  
591 S496A KI group compared to those in the WT group. To determine the phenotypes of cells in the  
592 plaques of these two groups of mice, we intentionally selected a similar size of plaques for our IMC  
593 analysis, as we described in the methods, assuming that this would make a fairer comparison of the  
594 plaque cell phenotype in the two groups of mice. By doing so, however, it is possible that we have  
595 selected plaques in which the inflammatory response was augmented, probably by p16<sup>34</sup>, PKC $\zeta$ <sup>35</sup>, and  
596 IL-6 induction, in the ERK5 S496A KI mice. Nevertheless, both KI and WT mice exhibited similar  
597 levels of regulation of p53, efferocytosis, antioxidants, and DNA damage response molecules'  
598 expression mediated by ERK5 S496 phosphorylation both *in vivo* (IMC data) and *in vitro* (cultured  
599 myeloid cells). These results suggest that neighboring cells' inflammatory conditions may play a  
600 critical role in p16 and other inflammatory molecules' expression in plaque macrophages as described  
601 previously<sup>36</sup>. Therefore, to detect phenotypic changes of macrophages in the plaque, it may be  
602 important to perform both *in vitro* and *in vivo* studies to exclude the temporal vessel environmental  
603 effects. Further investigation will be necessary to clarify these issues.

604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649

## SUPPLEMENTARY FIGURE LEGENDS

### Supplementary Figure 1. Body weights and serum cholesterol levels in ERK5 S496A KI mice after AAV-PCSK9 injection and fed a HFD *in vivo*, and mtROS detection by MitoSOX Red assay.

(A) WT BMDMs and ERK5 S496A KI BMDMs were treated with oxLDL (10  $\mu$ g/ml) for 0-30 minutes, and a immunoblotting analysis was performed using antibodies against the indicated proteins *in vitro* (left). The right graph represents densitometry data from 3 independent gels, one of which is shown in the left panel. n=3 (time course). Body weight (B) and HDL and LDL levels (C) in ERK5 S496A KI and WT mice after AAV/D377Y-mPCSK9 injection and fed a HFD. Echocardiographic parameters in ERK5 S496A KI and WT mice after AAV/D377Y-mPCSK9 injection and fed an HFD, LV FS (D): Left ventricular (LV) fractional shortening, LVPW;d (E): LV end-diastolic posterior wall thickness. (F, G) WT BMDMs and ERK5 S496A KI BMDMs were incubated with oxLDL as indicated. mtROS levels were detected by MitoSOX Red as described in the methods section *in vitro*. Cells treated with oxLDL or MitoTEMPOL (10  $\mu$ M) and vehicle control (G) were assayed 24 hours later. (H) BMDMs isolated from WT and ERK5 S496A KI mice fed a NCD or HFD for 4 months were cultured with the same medium *ex vivo*, and mtROS levels were detected by MitoSOX as described in Methods. (I) BMDMs were treated with indicated mutants and inhibitors as described in Fig.5, and mtROS production was detected by MitoSOX as described in the Methods. The applied statistical tests, sample number, and results in all figures are summarized in Table S3. All data are expressed as mean $\pm$ SD.

### Supplementary Figure 2. ERK5 S496A mutation and SASP components and DNMT3a in MCs ECs, and VSMCs *in vivo*.

(A-C) Traditional immunofluorescence staining strengthens the results obtained from IMC. To determine the p53, TRX, and DNMT3a expression in macrophage, we selected the Mac3-positive area and detected the signal intensity of p53, TRX, and DNMT3a in the Mac3-positive area. We used IgG control in place of each primary antibody with a section of each tissue sample to evaluate nonspecific staining. The area surrounded by the white dashed lines were designated as the Mac3-positive area. In Mac3-positive MC areas in the plaques (white dashed lines), p53 expression (A) was lower (n=6, 5) and TRX expression (B) (n=6, 5) and DNMT3a expression (C) (n=5, 7) were higher in ERK5 S496A KI cells than in WT cells. Scale bar=100  $\mu$ m. Data are expressed as mean $\pm$ SD. (D) Single-cell expression level of each marker in EC-like clusters between WT and ERK5 S496A KI plaques. TRX expression levels in #3 and #7; DNMT3a and GAS6 in #5, and #6; TYRO3 in #6; and IL-6 in #5 were increased in ERK5 S496A KI cells compared to in WT cells. We did not detect any differences in the expression of p53 and TOP2 $\beta$  between WT and ERK5 S496A KI. The Y-axis indicates the mean intensity, and black solid lines indicate the median value in each violin plot. Statistical significance was assessed by the Mann-Whitney test (n=2,536, 1,775 in cluster #5 and n=122, 202 in cluster #6). (E) The distance between the ECs in cluster #5 and the cells in each MC-like cluster was calculated by VIS software in the IMC analysis. The distance between EC-like cluster #5 and MC-like cluster #8 was shorter in ERK5 S496A KI cells than in WT cells (n=2484, 1781). Black solid lines indicate the median value in the violin plot. Statistical significance was assessed by the Mann-Whitney test. The images show EC-like cluster #5 and MC-like cluster #8 in WT (left) and ERK5 S496A KI (right) cells. White dashed lines indicate the surface of the plaque. L: lumen. Scale bar=100  $\mu$ m. (F) BMDMs

650 migration was determined in the Boyden chamber system after seeding BMDMs in the upper insert and  
651 the addition of oxLDL (10  $\mu$ g/ml) in the lower chamber. Analysis of BMDMs migration (number of  
652 migrating cells per field) for each group. **(G)** p16, p-TERF2IP, and p53 expression in MC (n=14,069  
653 cells). The Y-axis indicates the mean intensity, and solid black lines indicate the median value in each  
654 violin plot. **(H)** Single-cell analysis of p16 and Ki67 expression in MC *in vivo* (left upper panel). The  
655 log scaled ratio of Ki67 and p16 of selected cells by  $\log_{10}(\text{expression of Ki67}/\text{expression of p16})$ , and  
656 the cutoff of ratio with  $\log_{10}(-0.072)$  (left lower panel). The single-cell expression level of p-PKC $\zeta$  and  
657 p16 between WT and ERK5 S496A KI plaque tissues (right panels). **(I, J)** Single-cell analysis of p53  
658 and Ki67 expression in CD31<sup>+</sup> cells (I, n=4,635 cells) and  $\alpha$ -SMA<sup>+</sup> cells (G, n=1,276 cells) *in vivo*  
659 (upper panels). The log scaled ratio of Ki67 and p53 of selected cells by  $\log_{10}(\text{expression of Ki67}/\text{expression of p53})$   
660 (lower panels), and the cutoff of ratio with  $\log_{10}(-0.633)$  (J, left lower panel).  
661 Although the linear equation of p53 and ki67 in ECs is  $y=1.07x+0.26$ ,  $R^2 = 0.08$  suggests that the  
662 correlation of p53 and Ki67 in ECs is very low. **(K)** The single-cell expression level of each marker in  
663  $\alpha$ -SMA<sup>+</sup> cells clusters between WT (n=687 cells) and ERK5 S496A KI (n=589 cells) plaque tissues.  
664 The Y-axis indicates the mean intensity, and solid black lines indicate the median value in each violin  
665 plot. The applied statistical tests, sample number, and results in all figures are summarized in Table S3.  
666

667 **Supplementary Figure 3. Role of ERK5 S496 phosphorylation in hypercholesterolemia-induced**  
668 **MCs reprogramming to SASP in *ex vivo* (Quantification of Figure 3F).**  
669

670 The graphs represent densitometry data from 5 independent gels, one of which is shown in Figure 3F.  
671 The applied statistical tests, sample number, and results in all figures are summarized in Table S3. The  
672 data are mean $\pm$ SD, \*\* $P < 0.01$ , \* $P < 0.05$ .  
673

674 **Supplementary Figure 4. Macrophage polarization and cytokines secretion.**  
675

676 **(A, B)** Indicated mRNA levels were detected by qRT-PCR in BMDMs isolated from WT and ERK5  
677 S496A KI mice fed with NCD or HFD *ex vivo*. **(C)** Cytokine profiling in mouse serum from WT and  
678 ERK5 S496A KI mice after 4 months of HFD and AAV-PCSK9 injection was detected by Mouse  
679 Inflammatory Array (AAM-INF-1-4, Ray Biotech, Inc) *in vivo*. The applied statistical tests, sample  
680 number, and results in all figures are summarized in Table S3. The data are mean $\pm$ SD, \*\* $P < 0.01$ ,  
681 \* $P < 0.05$ .  
682

683 **Supplementary Figure 5. Role of ERK5 S496 phosphorylation in hypercholesterolemia-induced**  
684 **mitochondrial dysfunction *ex vivo*.**  
685

686 BMDMs isolated from WT and ERK5S496A KI mice fed with NCD or HFD were seeded on Seahorse  
687 plates. After 24 hours, OXPHOS and glycolysis parameters were measured. During extracellular flux  
688 analysis, cells were sequentially treated with **(A)** oligomycin (OM), carbonyl cyanide 4-  
689 (trifluoromethoxy) phenylhydrazone (FCCP), and rotenone plus antimycin A (ROT/AA) and used to  
690 assess OXPHOS parameters based on oxygen consumption rates. **(B)** The basal respiration, mt ATP  
691 production, maximal respiration, and spare respiratory capacity were calculated and plotted as oxygen  
692 consumption rates in pmoles/minutes. **(C)** Glucose (GLUC), OM, and 2-deoxyglucose (2-DG) were  
693 used to determine glycolysis parameters from extracellular acidification rates. **(D)** Glycolysis,  
694 glycolytic reserve, glycolytic capacity, and non-glycolytic acidification were calculated and plotted as



695 the extracellular acidification rate in mpH/minutes. The applied statistical tests, sample number, and  
696 results in all figures are summarized in Table S3. The data in A and C are mean±SEM, and B and D are  
697 mean±SD, \*\* $P<0.01$ , \* $P<0.05$ .

698

699 **Supplemental Figure 6. GO pathway analysis, enrichment plot, and GOBubble plot *ex vivo*.**

700

701 (A) GO and pathway analysis of DEGs. Top 15 significant GO terms (biological processes) associated  
702 with the identified DEGs. The vertical axis represents the GO category, and the horizontal axis  
703 represents the  $P$ -value of the significant GO terms. (B) Enrichment plots from GESA. GESA results  
704 showing G2M checkpoint and UV Response DN (genes downregulated in response to ultraviolet (UV)  
705 radiation). (C) Bubble plot indicates significantly enriched GO terms for the differentially expressed  
706 DEGs only in WT HFD and ERK5 S496A KI HFD mice. Size of the bubbles is proportional to the  
707 number of DEGs (adj.  $p$  value  $<0.05$ ) assigned to the GO term. The y-axis represents the negative  
708 logarithm of the adjusted  $p$  value (false discovery rate) for the GO terms, and the x-axis displays the  $z$ -  
709 score as calculated using the GOpot R-package<sup>37</sup>. The threshold for displaying the bubble labels was set  
710 to a  $\log(\text{FDR})$  of 1.0. GO terms belonging to biological process are green, molecular function are blue,  
711 and cellular component are red. (D) The graphs represent densitometry data from 3 independent gels,  
712 one of which is shown in Fig. 5I. The applied statistical tests, sample number, and results in all figures  
713 are summarized in Table S3. The data are mean±SD,  $n=5$ , \*\* $P<0.01$ .

714

715 **Supplemental Figure 7. NRF2 K518 SUMOylation mediated by ERK5 S496 phosphorylation**  
716 **inhibits SASP induction *in vitro* (Quantification of Figure 5).**

717

718 The graphs represent densitometry data from 5 independent gels, one of which is shown in Figure 5. The  
719 applied statistical tests, sample number, and results in all figures are summarized in Table S3. The data  
720 are mean±SD, \*\* $P<0.01$ , \* $P<0.05$ .

721

722 **Supplemental Figure 8. NRF2 K518 SUMOylation mediated by ERK5 S496 phosphorylation**  
723 **inhibits SASP induction (Quantification of Figure 6J).**

724

725 (A-B) BMDMs isolated from WT and ERK5S496A KI mice fed with NCD or HFD for 4 months were  
726 cultured with same medium. Cell lysates were immunoprecipitated with anti-NRF2 and immunoblotted  
727 with indicated antibodies *ex vivo*. Representative images from 3 independent experiments are shown.

728 (B) The graphs represent densitometry data from 3 independent gels, one of which is shown in A. (C)

729 The graphs represent densitometry data from 5 independent gels, one of which is shown in Figure 6J.

730 The applied statistical tests, sample number, and results in all figures are summarized in Table S3. The  
731 data are mean±SD, \*\* $P<0.01$ .

732

733

**Supplementary Table 1. Antibody panel for IMC**

	<b>Antigen</b>	<b>Vendor</b>	<b>Cat#</b>	<b>Metal tag</b>
Endothelial cells	CD31	R&D	AF3628	143Nd
	p-Tyrosine	Fluidigm	3144024D	144Nd
Myeloid cells	CD107b	Invitrogen	14-1072-85	145Nd
	TOP2 $\beta$	R&D	MAB6348	147Sm
Vascular smooth muscle cells	$\alpha$ -SMA	Fluidigm	3141017D	141Pr
Antioxidant	Thioredoxin (Trx)	Proteintech	14999-1-AP	148Nd
Myeloid cells	CD11b	Fluidigm	3149028D	149Sm
	p-PKC $\zeta$ (T410)	Abclonal	AP0520	150Nd
	p-TERF2IP (S205)	Homemade		151Eu
Anti-inflammation	p-AMPK alpha (T172)	Affinity Biosciences	AF3423	152Sm
Chemotaxis	CCR7	Biorbyt	orb547290	155Gd
Efferocytosis	Tyro3	R&D	MAB759	156Gd
Efferocytosis	Gas6	Abclonal	A8545	158Gd
	p90RSK1	StressMarq	SPC-147F	159Tb
	p-p90RSK (S380)	Bioworld	BS4870	160Gd
Endothelial cells	ERG	Biorbyt	orb192164	161Dy
Senescence	p16	Abcam	ab54210	162Dy
Inflammation	IL-6	R&D	AF-406-NA	163Dy
M2 marker	Arginase-1	Fluidigm	3164027D	164Dy
Senescence	p53	Abcam	ab131442	165Ho
Endothelial cells	vWF	Millipore	AB7356	166Er
Proliferation	Ki67	Fluidigm	3168022D	168Er
CH driver	DNMT3a	Novus	NB120-13888	170Er
	p-ERK1/2	Fluidigm	3171021D	171Yb
CH driver	p-JAK2	Abcam	ab219728	173Yb
	YAP	Abcam	ab56701	174Yb
	p-YAP (Y357)	Abcam	ab62751	175Lu
DNA	Ir DNA-intercalator	Fluidigm	201192A	191Ir
DNA	Ir DNA-intercalator	Fluidigm	201192A	193Ir

734

735 RRID number for each antibody was described in Supplementary Table 5.

736

737 **Supplementary Table 2. List of Real-time PCR primers.**

738 Primers Sequences

739 IL-1 $\beta$ -F 5'-CTACAGGCTCCGAGATGAACAA-3'740 IL-1 $\beta$ -R 5'-TCCATTGAGGTGGAGAGCTTTC-3'741 TNF $\alpha$ -F 5'-GGCTGCCCCGACTACGT-3'742 TNF $\alpha$ -R- 5'-AGGTTGACTTTCTCCTGGTATGA-3'743  $\beta$ -ACTIN-F 5'-AGAGGGAAATCGTGCGTGAC-3'744  $\beta$ -ACTIN-R 5'-CAATAGTGATGACCTGGCCGT-3'

745 iNOS-F 5'-TCCTGGAGGAAGTGGGCCGAAG3'

746 iNOS-R 5'-CCTCCACGGGCCCCGGTACTC-3'

747 Arg1-F 5'-CAGAAGA- ATGGAAGAGTCAG-3'

748 Arg1-R 5'-CAGATATGCAGGGAGTCAC- C-3'

749 Ym1-F 5'-GCAGAAGCTCTCCAGAAGCAATCCTG-3

750 Ym1- R 5'-ATTGGCCTGTCCTTAGCCCAACTG-3'

751 Fizz1-F 5'-GCTGATGGTCCCAGTGAATAC-3

752 Fizz1-R 5'-CCAGTAGCAGTC- ATCCCAGC-3

753

754 **Supplementary Table 3.** The applied statistical methods and results for each figure.

755

756 **Supplementary Table 4.** Controls for each relative value.

757

758 **Supplementary Table 5.** RRID number for each antibody, cells, software tools, mice, and plasmids.

759

760 Major Resources Table

761

762 **Raw data**

763

764 **File 1. The intensity of each protein in myeloid cells (MCs)-like cells in the plaques from**  
765 **hypercholesterolemia wild type and ERK5 S496A KI mice fed a high-fat diet.**

766

767 Wild type mice (Mouse A-G, cell number #1-7903) and ERK5 S496A KI mice (Mouse H-M, cell  
768 number #7904-14069) raw intensity data were shown.

769

770 **File 2. The intensity of each protein (Fig. S2D, I) in endothelial cells (ECs)-like cells in the**  
771 **plaques from hypercholesterolemia wild type and ERK5 S496A KI mice fed a high-fat diet.**


772

773 **File 3. The intensity of each protein (Fig. S2J, K) in  $\alpha$ -SMA<sup>+</sup> cells in the plaques from**  
774 **hypercholesterolemia wild type and ERK5 S496A KI mice fed a high-fat diet.**

775









776

777





Supplementary Figure 1



**G****H****I CD31<sup>+</sup> clusters****J  $\alpha$ -SMA<sup>+</sup> cells**




K






Supplement Figure 3








Supplement Figure 4




Supplement Figure 5




ID	Description
GO:0007049	cell cycle
GO:0006974	cellular response to DNA damage stimulus
GO:0015031	protein transport
GO:0043066	negative regulation of apoptotic process
GO:0006355	regulation of transcription, DNA-templated
GO:0008152	metabolic process
GO:0010824	regulation of centrosome duplication
GO:0000398	mRNA splicing, via spliceosome
GO:0006397	mRNA processing
GO:0005634	nucleus
GO:0005737	cytoplasm
GO:0005622	intracellular
GO:0048471	perinuclear region of cytoplasm
GO:0005765	lysosomal membrane
GO:0005768	endosome
GO:0000139	Golgi membrane
GO:0005783	endoplasmic reticulum
GO:0003676	nucleic acid binding
GO:0046872	metal ion binding
GO:0000166	nucleotide binding
GO:0003723	RNA binding
GO:0031625	ubiquitin protein ligase binding
GO:0003824	catalytic activity



Supplement Figure 6



Supplement Figure 7



Supplement Figure 8